Northern Trust’s 10x Genomics TXG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $103M | Sell |
1,137,811
-6,216
| -0.5% | -$364K | 0.01% | 740 |
|
|
2026
Q2 | $43.9M | Buy |
1,144,027
+96,022
| +9% | +$2.52M | 0.01% | 1286 |
|
|
2026
Q1 | $22.2M | Buy |
1,048,005
+54,625
| +5% | +$1.09M | ﹤0.01% | 1610 |
|
|
2025
Q4 | $16.2M | Sell |
993,380
-45,883
| -4% | -$693K | ﹤0.01% | 1807 |
|
|
2025
Q3 | $12.1M | Buy |
1,039,263
+29,951
| +3% | +$391K | ﹤0.01% | 2004 |
|
|
2025
Q2 | $11.7M | Buy |
1,009,312
+460,280
| +84% | +$4.2M | ﹤0.01% | 1972 |
|
|
2025
Q1 | $4.79M | Sell |
549,032
-12,634
| -2% | -$159K | ﹤0.01% | 2425 |
|
|
2024
Q4 | $8.07M | Sell |
561,666
-31,923
| -5% | -$504K | ﹤0.01% | 2245 |
|
|
2024
Q3 | $13.4M | Sell |
593,589
-55,221
| -9% | -$1.14M | ﹤0.01% | 1889 |
|
|
2024
Q2 | $12.6M | Buy |
648,810
+56,948
| +10% | +$1.49M | ﹤0.01% | 1855 |
|
|
2024
Q1 | $22.2M | Buy |
591,862
+122,227
| +26% | +$5.37M | ﹤0.01% | 1518 |
|
|
2023
Q4 | $26.3M | Sell |
469,635
-2,450
| -0.5% | -$107K | ﹤0.01% | 1423 |
|
|
2023
Q3 | $19.5M | Buy |
472,085
+11,599
| +3% | +$603K | ﹤0.01% | 1561 |
|
|
2023
Q2 | $25.7M | Buy |
460,486
+3,835
| +0.8% | +$208K | ﹤0.01% | 1421 |
|
|
2023
Q1 | $25.5M | Buy |
456,651
+58,937
| +15% | +$2.75M | 0.01% | 1395 |
|
|
2022
Q4 | $14.5M | Buy |
397,714
+4,779
| +1% | +$156K | ﹤0.01% | 1760 |
|
|
2022
Q3 | $11.2M | Buy |
392,935
+6,341
| +2% | +$242K | ﹤0.01% | 1897 |
|
|
2022
Q2 | $17.5M | Sell |
386,594
-88,125
| -19% | -$4.57M | ﹤0.01% | 1623 |
|
|
2022
Q1 | $36.1M | Buy |
474,719
+5,285
| +1% | +$462K | 0.01% | 1265 |
|
|
2021
Q4 | $69.9M | Sell |
469,434
-50,359
| -10% | -$7.71M | 0.01% | 868 |
|
|
2021
Q3 | $75.7M | Buy |
519,793
+42,144
| +9% | +$7.24M | 0.01% | 806 |
|
|
2021
Q2 | $93.5M | Buy |
477,649
+68,786
| +17% | +$12.4M | 0.02% | 707 |
|
|
2021
Q1 | $74M | Buy |
408,863
+13,132
| +3% | +$2.27M | 0.01% | 834 |
|
|
2020
Q4 | $56M | Buy |
395,731
+107,242
| +37% | +$15.6M | 0.01% | 984 |
|
|
2020
Q3 | $36M | Buy |
288,489
+105,361
| +58% | +$11.1M | 0.01% | 1145 |
|
|
2020
Q2 | $16.4M | Buy |
183,128
+158,666
| +649% | +$12.4M | ﹤0.01% | 1777 |
|
|
2020
Q1 | $1.52M | Buy |
24,462
+1,777
| +8% | +$139K | ﹤0.01% | 3004 |
|
|
2019
Q4 | $1.73M | Buy |
22,685
+14,471
| +176% | +$870K | ﹤0.01% | 3205 |
|
|
2019
Q3 | $414K | Buy |
+8,214
| New | +$455K | ﹤0.01% | 3587 |
|
Other funds holding TXG
Northern Trust's TXG Position: Q3 2026 in Review
Northern Trust reduced its 10x Genomics (TXG) stake by 0.54% in Q3 2026, selling an estimated $364K and leaving 1,137,811 shares worth $103M. The position accounts for 0.01% of the portfolio, ranked #740.
Northern Trust first reported a position in TXG in Q3 2019 and has held it in 29 quarters since. 491 funds tracked by Wall St. Rank hold TXG as of Q3 2026.
- Northern Trust held 1,137,811 shares of 10x Genomics worth $103M as of Q3 2026.
- Northern Trust sold 6,216 10x Genomics shares in Q3 2026, an estimated $364K.
- 10x Genomics made up 0.01% of Northern Trust's portfolio in Q3 2026, its #740 holding.
- Northern Trust first reported a position in 10x Genomics in Q3 2019 and has held it in 29 quarters since.
- 491 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.
Based on Northern Trust's 13F filing for Q3 2026, filed 16 Nov 2026.